Vitamin D3

Vitamin D3 (cholecalciferol) is one of the most-researched vitamins in modern supplement science, with a literature spanning bone density and fracture prevention, cardiovascular and cancer outcomes (the past decade's megatrials), immune function, mood, and pregnancy. The body activates D3 through liver and kidney hydroxylation into its hormone form, which binds vitamin D receptors throughout the body to regulate calcium and modulate gene expression - which is part of why the supplement is studied across such a wide range of outcomes. D3 has largely displaced D2 in supplement trials because it raises and sustains blood levels more effectively and is the form used in nearly all major modern studies.

The outcome dimensions covered most heavily are bone density, falls, and fracture risk in older adults; cardiovascular and cancer outcomes in the past decade of megatrials; immune-related outcomes (especially in the post-2020 wave); and mood/depression. Pediatric rickets prevention anchors the foundational end of the literature. Newer growth areas include autoimmune conditions, pregnancy outcomes, and respiratory infection prevention.

Demographically, postmenopausal women dominated the bone-density era and still feature heavily in the long-running trials. Megatrials enrolling broader adult populations have widened the picture, but a central modifier of who responds to supplementation is baseline vitamin D status - measured as serum 25-hydroxyvitamin D - which trials use both as an enrollment criterion and, in many cases, as the primary endpoint. Trials enrolling already-replete populations typically show smaller effects than trials enrolling deficient populations, which is part of why pooled effect estimates can mask meaningful subgroup signals.

Vitamin D3 is generally well-tolerated at typical supplement doses. Toxicity is rare but possible at sustained very high intakes, with hypercalcemia as the principal warning sign. The IOM tolerable upper limit for adults is 4,000 IU/day; the 2011 Endocrine Society guideline tied upper limits to age and clinical circumstances, and the 2024 guideline defers to the DRIs. Drug interactions include thiazide diuretics (additive calcium retention), corticosteroids (impaired vitamin D metabolism), and bile-acid sequestrants or the fat-blocking type of weight-loss medicine (reduced fat-soluble absorption). Conditions that warrant clinician guidance before supplementing include primary hyperparathyroidism, granulomatous diseases such as sarcoidosis, and chronic kidney disease, all of which can alter vitamin D handling. Source guidance includes the IOM Dietary Reference Intakes report and the Endocrine Society clinical practice guidelines.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.